Gilead Sciences Inc (GILD.O)
25 Sep 2017
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|65||2016||Executive Chairman of the Board|
|56||2016||Chief Executive Officer, Director|
|54||2014||Chief Financial Officer, Executive Vice President|
|59||2016||Chief Operating Officer|
|61||2007||Executive Vice President - Research and Development, Chief Scientific Officer|
- BRIEF-China Food and Drug Administration approves Gilead’s Sovaldi
- BRIEF-Gilead receives approval in Canada for expanded indication of epclusa
- BRIEF-Gilead Sciences entered into a $6 bln term loan facility credit agreement - SEC Filing
- BRIEF-Gilead Sciences to present at the Morgan Stanley Global Healthcare conference
- BRIEF-Gilead Sciences files for potential mixed shelf size not disclosed